A recent white paper (“The Association Between Drug Rebates and List Prices”) narrowly suggests an association between list prices for brand drugs and the rebate practices of pharmacy benefit managers (PBMs) and insurers, despite an underlying methodology that is notably broader
(Washington, D.C.) — The Pharmaceutical Supply and Payment Chain Coalition issued the following statement in response to the Administration’s 100-day review of the actions needed to address vulnerabilities in our nation’s pharmaceutical supply chain and what measures need to be taken in order
With the recent launch of a new adalimumab biosimilar, the U.S. biosimilar market is becoming more competitive, increasing the potential for these more affordable options to play a critical role in helping to lower prescription drug costs for Americans. As biosimilar competition
As a reminder, the U.S. House of Representatives Committee on Oversight and Reform previously found, in a 2021 report, that PBM-negotiated rebates are not correlated with the list prices set by drug companies. The report also finds that “drug companies have
In case you missed it, an expert witness who testified before the U.S. House Committee on Oversight and Accountability during a hearing yesterday on pharmacy benefit companies underscored that misguided policies targeting pharmacy benefits will lead to higher prescription drug
(Washington, D.C.) — The Pharmaceutical Care Management Association (PCMA) today released a new, first-of-its-kind, progress report on the work PCMA member pharmacy benefit companies are doing to deepen the industry’s commitment to promote health equity and reduce health disparities. This
In case you missed it, a new article in Inside Health Policy reported that “Investors for eight major drug companies will vote throughout the spring on 11 proposals aimed at reducing the use of common drug patent practices and pharmaceutical lobbying activities
Newsroom Read More with Amanda Frost VIEW MORE VIEW MORE FROM JC SCOTT Katie Payne Senior Vice President, Public Affairs kpayne@pcmanet.org Greg Lopes Vice President, Public Affairs glopes@pcmanet.org 202-756-5713 Mike Baldyga Director, Public Affairs mbaldyga@pcmanet.org 202-756-5714 FOR YOUR INFORMATION The
Misguided Legislation Targets Pharmacy Benefits That Save Employers and Patients an Average of $1,000 Per Person Each Year and Undermines Market Forces in Health Care In case you missed it, leading economic experts and competition watchdogs have overwhelmingly expressed concern
©2024 PCMA. All Rights Reserved.
